On Tuesday night, the US Food and Drug Administration (FDA) announced that the company's best-seller Wegovy is now approved in tablet form on the US market.
Wegovy, which is a so-called GLP-1 drug, has already been sold in injection form. Unlike the injections, which are taken once a week, the tablets can be taken once a day.
The news gave a stock market boost to Novo Nordisk, which earlier in the year had headwinds due to cheaper variants of Wegovy popping up among competitors.
